• +1-646-491-9876
    • +91-20-67278686

    Search

    Tourette Syndrome-Pipeline Review H2 2017

    Tourette Syndrome-Pipeline Review H2 2017

    • Report Code ID: RW0001881439
    • Category Life Sciences
    • No. of Pages 75
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Tourette Syndrome-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome-Pipeline Review H2 2017 provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

    Tourette syndrome (TS) is a neurological disorder characterized by repetitive stereotyped involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements facial grimacing shoulder shrugging and head or shoulder jerking. Other symptoms include touching the nose smelling objects flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants stimulant medications and behavior therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Preclinical and Unknown stages are 1 6 1 1 and 1 respectively. Similarly the Universities portfolio in Preclinical stages comprises 1 molecules respectively.

    Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Tourette Syndrome-Overview
    Tourette Syndrome-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Tourette Syndrome-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Tourette Syndrome-Companies Involved in Therapeutics Development
    Abide Therapeutics Inc
    Catalyst Pharmaceuticals Inc
    Neurocrine Biosciences Inc
    Psyadon Pharmaceuticals Inc
    Reviva Pharmaceuticals Inc
    Synchroneuron Inc
    Teva Pharmaceutical Industries Ltd
    Therapix Biosciences Ltd
    Tourette Syndrome-Drug Profiles
    (amfetamine + guanfacine hydrochloride)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ABX-1431-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    acamprosate calcium SR-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CPP-115-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    deutetrabenazine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dronabinol + palmidrol-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ecopipam hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RP-5063-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    valbenazine tosylate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vigabatrin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tourette Syndrome-Dormant Projects
    Tourette Syndrome-Discontinued Products
    Tourette Syndrome-Product Development Milestones
    Featured News & Press Releases
    May 23 2017 Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA For Treatment of Tourette Syndrome
    May 08 2017 Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome
    Apr 18 2017 Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America
    Jan 17 2017 Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette's Syndrome in Children
    Jan 17 2017 Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA (valbenazine) in Adults with Tourette Syndrome
    Jan 04 2017 Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Yale University for Treating Tourette's Syndrome Using Cannabinoid-based Drug
    Aug 31 2016 Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA for VMAT2 Inhibitor Valbenazine
    Jul 28 2016 Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
    Jun 15 2016 Therapix Biosciences Filed an Application with the FDA to Approve an Orphan Designation for the Drug Developed Based on the Entourage Technology for Treating Tourette Syndrome
    Feb 03 2016 Psyadon Announces Positive Independent Review of Phase 2b Study of Ecopipam for the Treatment of Tourette's Syndrome in Children
    Feb 02 2016 Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
    Dec 16 2015 Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
    Oct 20 2015 Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
    Jan 14 2015 Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population
    Oct 02 2014 Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Tourette Syndrome H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Tourette Syndrome-Pipeline by Abide Therapeutics Inc H2 2017
    Tourette Syndrome-Pipeline by Catalyst Pharmaceuticals Inc H2 2017
    Tourette Syndrome-Pipeline by Neurocrine Biosciences Inc H2 2017
    Tourette Syndrome-Pipeline by Psyadon Pharmaceuticals Inc H2 2017
    Tourette Syndrome-Pipeline by Reviva Pharmaceuticals Inc H2 2017
    Tourette Syndrome-Pipeline by Synchroneuron Inc H2 2017
    Tourette Syndrome-Pipeline by Teva Pharmaceutical Industries Ltd H2 2017
    Tourette Syndrome-Pipeline by Therapix Biosciences Ltd H2 2017
    Tourette Syndrome-Dormant Projects H2 2017
    Tourette Syndrome-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Tourette Syndrome H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Top 10 Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Abide Therapeutics Inc
    Catalyst Pharmaceuticals Inc
    Neurocrine Biosciences Inc
    Psyadon Pharmaceuticals Inc
    Reviva Pharmaceuticals Inc
    Synchroneuron Inc
    Teva Pharmaceutical Industries Ltd
    Therapix Biosciences Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//tourette-syndrome-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//tourette-syndrome-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//tourette-syndrome-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments